*Purpose/Agenda:* To review individual grant applications.

Name of SEP: Clinical Sciences.

Date: April 28, 1997. Time: 10:00 a.m.

Place: Marriott Courtyard, Crystal City, VA. Contact Person: Dr. J. Terrell Hoffeld,

Scientific Review Administrator, 6701 Rockledge Drive, Room 4116, Bethesda, Maryland 20892, (301) 435–1781.

Name of SEP: Behavioral and

Neurosciences.

Date: April 29, 1997. Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 5178, Telephone Conference.

Contact Person: Dr. Joseph Kimm, Scientific Review Administrator, 6701 Rockledge Drive, Room 5178, Bethesda, Maryland 20892, (301) 435–1249.

*Name of SEP:* Chemistry and Related Sciences.

Date: April 29, 1997. Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 5150,

Telephone Conference.

Contact Person: Dr. Zakir Bengali, Scientific Review Administrator, 6701 Rockledge Drive, Room 5150, Bethesda, Maryland 20892, (301) 435–1742.

*Name of SEP:* Chemistry and Related Sciences.

Date: April 30-May 1, 1997.

Time: 4:30 p.m.

Place: Ramada Inn, Bethesda, MD. Contact Person: Dr. Zakir Bengali, Scientific Review Administrator, 6701 Rockledge Drive, Room 5150, Bethesda, Maryland 20892, (301) 435–1742.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

Name of SEP: Behavioral and Neurosciences.

Date: May 6, 1997. Time: 10:00 a.m.

Place: NIH, Rockledge 2, Room 5182,

Telephone Conference.

Contact Person: Dr. Carl Banner, Scientific Review Administrator, 6701 Rockledge Drive, Room 5182, Bethesda, Maryland 20892, (301) 435–1251.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 15, 1997.

#### LaVeen Ponds,

Acting Committee Management Officer, NIH. [FR Doc. 97–10239 Filed 4–18–97; 8:45 am] BILLING CODE 4140–01–M

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **Public Health Service**

National Institute of Environmental Health Sciences; National Toxicology Program; Announcement of Nominated Chemicals Approved and Under Consideration for Toxicological Studies by the National Toxicology Program (NTP)—Request for Comments

As part of an effort to earlier inform and obtain public input into the selection of chemicals for evaluation, the National Toxicology Program (NTP) routinely announces in the **Federal Register** chemicals nominated to the Program, recommended for toxicological

studies by the Interagency Committee for Chemical Evaluation and Coordination (ICCEC), and approved for study by the NTP Executive Committee. This announcement will allow interested parties to comment and provide information on chemicals under consideration for study. The Program would welcome receiving toxicology and carcinogenesis information from completed, ongoing, or planned studies by others, as well as current production data, human exposure information, use patterns, and environmental occurrence for any of the chemicals listed in this announcement. To provide comments or information, please contact Dr. William Eastin at the address given below within 60 days of the appearance of this announcement.

At their meeting on February 7, 1997, the ICCEC reviewed and recommended twelve chemicals or chemical classes for metabolism, toxicity, or carcinogenicity studies. On February 27, 1997, the NTP Executive Committee reviewed and approved the recommendations of the ICCEC. Chemicals with CAS numbers, nomination source, types of studies under consideration, and other supporting information are given in the table. Contact may be made by mail to: Dr. William Eastin, NIEHS/NTP, P. O. Box 12233, Research Triangle Park, North Carolina 27709; by telephone at (919) 541-7941; by FAX at (919) 541-4714; or by email at Eastin@NIEHS.NIH.GOV.

Dated: April 10, 1997.

#### Kenneth Olden,

Director, National Institute of Environmental Health Sciences and National Toxicology Program.

### ATTACHMENT—CHEMICALS APPROVED FOR STUDY BY THE NTP EXECUTIVE COMMITTEE ON FEBRUARY 27, 1997

Chemical (CAS number)	Nomination source	Testing recommendations	Study rationale remarks
Bromodichloroacetic Acid (71333–14–7).	EPA	Carcinogenicity; Reproductive, neurotoxicity screen; Genetic toxicity.	Water disinfectant byproduct, part of a class study.
2-Butyne-1,4-diol (110-65-6)	NIEHS	Short and long-term toxicity; re- productive, neurotoxicity screen; metabolism; mechanistic studies.	Industrial intermediate, stabilizer, corrosion inhibitor.
			Coordinate with EPA the testing planned through OECD-SIDS.
Dibromoacetonitrile (3252-42-5)	EPA	Carcinogenicity; Reproductive, neurotoxicity screen; in vivo micronucelus.	Water disinfectant byproduct, part of a class study.
trans-1,4-Dichloro-2-butene (110–57–6).	NIEHS	Carcinogenicity; Short-term toxicity.	High production volume.
,		,	Chemical intermediate.
			Human exposure not well defined.
			Extensive toxicity and carcino- genesis data received from in- dustry may lead to deferral.
Ethyl Bromoacetate (105-36-2)	NCI	Metabolism studies	May hydrolyze to bromoacetic acid.

## ATTACHMENT—CHEMICALS APPROVED FOR STUDY BY THE NTP EXECUTIVE COMMITTEE ON FEBRUARY 27, 1997—Continued

Chemical (CAS number)	Nomination source	Testing recommendations	Study rationale remarks
$\alpha$ -Hydroxy Acids (and their salts)	FDA	Phototoxicity; Chronic toxicity	Odorant in toxic gases. Chemical intermediate. FDA's FY 1997 priority nomination.
Glycolic Acid (79–14–1)			Skin care product uses.
Lactic Acid (50–21–5)			Class study.
Methyl Isobutyl Ketone (108–10–1)	NCI	Carcinogenicity	High production volume.
			Environmental exposure.
Methylamine (74–89–5)	NCI; Private individual	Pharmacokinetics	Component of many foods.
β-Myrcene (123–35–3)	NIEHS	Metabolism studies; Consider for carcinogenicity.	May be metabolized to a diepoxide.  High production and high level of
			natural exposure.
Octachloronaphthalene (2234–13–1).	NCI	Liver P450 enzyme induction; Estrogenic activity.	Potential to bioaccumulate and enter food chain as component of halowaxes.
Propargyl Alcohol (107–19–7)	NCI	Subchronic toxicity	High production and human exposure.
Sodium Thioglycolate (367–51–1)	NCI	Reproductive toxicity	High production and occupational and human exposure in hair care products.

[FR Doc. 97–10180 Filed 4–18–97; 8:45 am] BILLING CODE 4140–01–M

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

## Supplemental Awards for Women and Children's Residential Treatment Program Grantees

**AGENCY:** Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

ACTION: Availability of Supplemental Funds for Currently Funded Grantees in CSAT Woman and Children's Program for Pregnant and Postpartum Women (PPW) and Residential Treatment Program for Women and their Children (RWC).

**SUMMARY:** This notice is to inform the public that CSAT is making available approximately \$1.5 million for supplemental awards in FY 1997 to existing PPW and RWC grantees in the Women and Children's Program to expand and/or enhance services for children. Competition is being limited to the 53 currently funded PPW and RWC grantees with at least one year of funding remaining as of September 30, 1997 (as reflected on the current Notice of Grant Award). Given the necessarily short implementation timeframe and limited funds available for this activity, and the need for reliable evaluation designs that can easily incorporate

additional children's services, the existing CSAT treatment grant projects for women and children are the only projects that can effectively implement the services to be provided under this GFA. These projects have already demonstrated that they can effectively provide therapeutic services for children, and operate within well established infrastructures with knowledgeable, trained staff in addressing children's issues. They also have demonstrated solid and proven experience in the provision of services for children. Finally, these projects are required by legislation to provide comprehensive services for children of addicted women. These supplements will enhance the delivery of the statutorily-required services. Applications will be considered for funding on the basis of their overall technical merit as determined through the peer and CSAT National Advisory Council review process.

Supplemental awards will be provided to PPW and RWC grantees to expand and/or enhance services for children of substance abusing parents. Grantees may apply for support to expand and/or enhance services for children within the scope of the current residential treatment grant, and may also apply for funds to increase the availability of child care services for women in any component of treatment under the administration of the subrecipient treatment provider. The maximum amount of any one grant award will be \$300,000.

**Authority:** Supplemental awards will be made under authority of sections 508 and

510 of the Public Health Service Act, as amended (42 U.S.C. 290bb–1 and 42 U.S.C. 290bb–3, respectively.)

**CONTACT:** Maggie Wilmore, Center for Substance Abuse Treatment, SAMHSA, Rockwall II Building, Suite 7A–145, 5600 Fishers Lane, Rockville, Maryland 20857 (Telephone: 301 443–8216).

The Catalog of Federal Domestic Assistance (CDFA) numbers are 93.101 for the PPW Program and 93.102 for the RWC Program.

Dated: April 15, 1997.

### Richard Kopanda,

Executive Officer, Substance Abuse and Mental Health Services Administration. [FR Doc. 97–10248 Filed 4–18–97; 8:45 am] BILLING CODE 4162–20–P

### **DEPARTMENT OF THE INTERIOR**

### Bureau of Land Management

[CO-078-97-1990-00]

# Supplemental Environmental Impact Statement (EIS) on Oil and Gas Development

**AGENCY:** Bureau of Land Management, Interior.

**ACTION:** Notice of intent to prepare a Supplemental Environmental Impact Statement (EIS) on Oil and Gas Development in the Glenwood Springs Resource Area, Colorado.

SUMMARY: Pursuant to sec. 102 of the National Environmental Policy Act of 1969 and sec. 202 and sec. 303 of the Federal Land Policy and Management Act of 1976, the Bureau of Land